XML 23 R11.htm IDEA: XBRL DOCUMENT
v3.23.2

Supplementary Balance Sheet Information | 6 Months Ended
--- | ---
Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract] |
Supplementary Balance Sheet Information | Note 5 – Supplementary Balance Sheet Information Property and equipment consist of the following (in thousands):
|  | June 30, 2023 |  |  | December 31, 2022 |
Lab equipment |  | $ | 6,038 |  |  | $ | 6,035 |
Leasehold improvements |  |  | 2,365 |  |  |  | 2,365 |
Computer equipment |  |  | 1,075 |  |  |  | 749 |
Furniture and fixtures |  |  | 349 |  |  |  | 349 |
Software |  |  | 325 |  |  |  | 324 |
Vehicles |  |  | 97 |  |  |  | 97 |
Construction in process |  |  | 16,338 |  |  |  | 2,947 |
|  |  | 26,587 |  |  |  | 12,866 |
Less accumulated depreciation |  |  | (7,591 | ) |  |  | (7,018 | )
Total property and equipment, net |  | $ | 18,996 |  |  | $ | 5,848 |
Depreciation expense for the three and six months ended June 30, 2023 was $0.3 million and $0.6 million, respectively, compared to $0.4 million and $0.8 million for the three and six months ended June 30, 2022, respectively. Intangible assets, excluding goodwill, consist of the following (in thousands):
|  | June 30, 2023 |  |  | December 31, 2022 |
|  | Cost |  |  | Accumulated Amortization |  |  | Net Carrying Value |  |  | Cost |  |  | Accumulated Amortization |  |  | Net Carrying Value |
Intangible assets subject to amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Patents |  | $ | 1,945 |  |  | $ | (699 | ) |  | $ | 1,246 |  |  | $ | 1,880 |  |  | $ | (647 | ) |  | $ | 1,233 |
Purchased technology |  |  | 16,900 |  |  |  | (9,389 | ) |  |  | 7,511 |  |  |  | 16,900 |  |  |  | (8,450 | ) |  |  | 8,450 |
Intangible assets not subject to amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks |  |  | 114 |  |  |  | — |  |  |  | 114 |  |  |  | 114 |  |  |  | — |  |  |  | 114 |
Total |  | $ | 18,959 |  |  | $ | (10,088 | ) |  | $ | 8,871 |  |  | $ | 18,894 |  |  | $ | (9,097 | ) |  | $ | 9,797 |
Amortization expense related to definite-lived intangible assets was $0.5 million and $1.0 million for both the three and six months ended June 30, 2023 and 2022, respectively. Future estimated amortization expense of intangible assets is (in thousands):
|  | As of June 30, 2023 |
Remainder of 2023 |  | $ | 990 |
2024 |  |  | 1,973 |
2025 |  |  | 1,967 |
2026 |  |  | 1,953 |
2027 |  |  | 1,003 |
2028 and thereafter |  |  | 871 |
Total |  | $ | 8,757 |
Accrued liabilities consist of the following (in thousands):
|  | June 30, 2023 |  |  | December 31, 2022 |
Compensation related accruals |  | $ | 3,913 |  |  | $ | 4,671 |
Accrued clinical trial expense |  |  | 1,270 |  |  |  | 1,232 |
Other expenses |  |  | 1,798 |  |  |  | 2,315 |
Total accrued liabilities |  | $ | 6,981 |  |  | $ | 8,218 |

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration